<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; BLUD</title>
	<atom:link href="http://www.stockbloghub.com/tag/blud/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(KCI) Kinetic Concepts Aquired by Apax Partners and Two Canadian Pension Funds</title>
		<link>http://www.stockbloghub.com/2011/07/14/kci-kinetic-concepts-aquired-by-apax-partners-and-two-canadian-pension-funds/79075</link>
		<comments>http://www.stockbloghub.com/2011/07/14/kci-kinetic-concepts-aquired-by-apax-partners-and-two-canadian-pension-funds/79075#comments</comments>
		<pubDate>Thu, 14 Jul 2011 16:43:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[AHS]]></category>
		<category><![CDATA[AMN Healthcare Services Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BLUD]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Immucor Inc.]]></category>
		<category><![CDATA[KCI]]></category>
		<category><![CDATA[Kinetic Concepts Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Smith & Nephew Plc]]></category>
		<category><![CDATA[SNN]]></category>
		<category><![CDATA[Total System Services Inc]]></category>
		<category><![CDATA[TSS]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79075</guid>
		<description><![CDATA[Private equity firm Apax Partners and two Canadian pension funds are set to acquire leading medical technology company Kinetic Concepts (KCI). The deal, including Kinetic&#8217;s outstanding debt, is valued at approximately $6.3 billion. As an independent global partnership, Apax exclusively focuses on long-term investment in growth companies. The acquisition of Kinetic is part of Apax’s intention to support deals in the financial &#38; business services, healthcare, media, retail &#38; consumer and technology sectors. However, probably its budget doesn’t permit such a big acquisition at this point, so Apax teamed up with the Canada Pension Plan Investment Board (CPPIB) and the Public Sector Pension Investment Board (PSP Investments) to get the deal done. As per the terms of the agreement, Kinetic’s shareholders will receive $68.50 in cash for each share of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/14/kci-kinetic-concepts-aquired-by-apax-partners-and-two-canadian-pension-funds/79075/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BLUD) Company News for July 6, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/07/06/blud-company-news-for-july-6-2011-corporate-summary/78433</link>
		<comments>http://www.stockbloghub.com/2011/07/06/blud-company-news-for-july-6-2011-corporate-summary/78433#comments</comments>
		<pubDate>Wed, 06 Jul 2011 15:47:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BLUD]]></category>
		<category><![CDATA[BTU]]></category>
		<category><![CDATA[EE]]></category>
		<category><![CDATA[El Paso Electric Company]]></category>
		<category><![CDATA[Energy Transfer Equity L.P.]]></category>
		<category><![CDATA[ETE]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Immucor Inc.]]></category>
		<category><![CDATA[JOE]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Oppenheimer Holdings Inc]]></category>
		<category><![CDATA[OPY]]></category>
		<category><![CDATA[Peabody Energy Corporation]]></category>
		<category><![CDATA[Southern Union Company]]></category>
		<category><![CDATA[SUG]]></category>
		<category><![CDATA[The St. Joe Company]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[Western Union Company]]></category>
		<category><![CDATA[WFC]]></category>
		<category><![CDATA[Williams Companies Inc.]]></category>
		<category><![CDATA[WMB]]></category>
		<category><![CDATA[WU]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78433</guid>
		<description><![CDATA[•    Share prices of Southern Union Co. (NYSE:SUG) rose 4.21% to close at $42.07 after Energy Transfer Equity, L.P. (NYSE:ETE) increased its bidding amount by 21% to $5 billion for the company, beating William&#8217;s (NYSE:WMB) bid of $4.9 billion •    U.S. mining giant Peabody Energy Corp. (NYSE:BTU) was amongst a consortium selected by the  Mongolian Government  to develop the Tavan Tolgoi  coal mining project in the Gobi Desert •    Analysts of Wells Fargo (NYSE:WFC) opined that a medical journal report about Medtronic’s (NYSE:MDT) spine device will slow down sales. The report could also lead to investigations by federal regulators •    Analysts at Oppenheimer &#38; Co. (NYSE:OPY) initiated coverage on shares of Zalicus, Inc. (NASDAQ:ZLCS) with an &#8220;Outperform&#8221; rating and a target price of $4.00 •    Shares of Immucor, Inc. (NASDAQ:BLUD) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/06/blud-company-news-for-july-6-2011-corporate-summary/78433/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BLUD) Immucor Purchased by TPG Capital for $1.9B</title>
		<link>http://www.stockbloghub.com/2011/07/06/blud-immucor-purchased-by-tpg-capital-for-1-9b/78440</link>
		<comments>http://www.stockbloghub.com/2011/07/06/blud-immucor-purchased-by-tpg-capital-for-1-9b/78440#comments</comments>
		<pubDate>Wed, 06 Jul 2011 15:45:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BLUD]]></category>
		<category><![CDATA[Immucor Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78440</guid>
		<description><![CDATA[Manufacturer and seller of automated systems and reagents, Immucor Inc. (BLUD) recently announced that it will be taken over by private equity group TPG Capital for $1.97 billion. As per the terms of the agreement, Immucor’s shareholders will receive $27 in cash for each share of the company, representing a premium of 30.2% over the closing price of the stock on July 1, 2011 and a premium of approximately 35.6% to Immucor&#8217;s average closing price over the last month. The deal is expected to be completed in the second half of 2011. Following this announcement, shares of Immucor surged 30% to $26.99 on Tuesday. The deal, however, is subject to regulatory approval and the support of the owners of a minimum of 84% of Immucor&#8217;s shares. TPG Capital will start ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/06/blud-immucor-purchased-by-tpg-capital-for-1-9b/78440/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BLUD) Immucor Third Quarter Earnings Meets Consensus Estimates</title>
		<link>http://www.stockbloghub.com/2010/04/01/blud-immucor-third-quarter-earnings-meets-consensus-estimates/32583</link>
		<comments>http://www.stockbloghub.com/2010/04/01/blud-immucor-third-quarter-earnings-meets-consensus-estimates/32583#comments</comments>
		<pubDate>Thu, 01 Apr 2010 16:39:52 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BLUD]]></category>
		<category><![CDATA[Immucor Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32583</guid>
		<description><![CDATA[Immucor Inc. (BLUD) announced third quarter 2010 (ending in Feb 2010) earnings per share (EPS) of 28 cents, in line with the Zacks Consensus Estimate and a penny higher than the year ago quarter. Net income for the quarter was $20.1 million, compared with $19.5 million for the same quarter in 2009. The company reported $80.5 million in revenues, an increase of 7% from $75.3 million in the year-ago period. The increase in revenues was primarily based on price increases and a positive impact of $1.8 million due to foreign exchange fluctuations. Volume contribution from reagents was negatively impacted by fewer shipping cycles in the current year as well as sales mix. While Immucor has recorded growth in its top line, its gross margin suffered due to costs related to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/01/blud-immucor-third-quarter-earnings-meets-consensus-estimates/32583/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BLUD) Immucor Third Quarter 2010 Earnings Preview</title>
		<link>http://www.stockbloghub.com/2010/03/29/blud-immucor-third-quarter-2010-earnings-preview/31748</link>
		<comments>http://www.stockbloghub.com/2010/03/29/blud-immucor-third-quarter-2010-earnings-preview/31748#comments</comments>
		<pubDate>Mon, 29 Mar 2010 21:21:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BLUD]]></category>
		<category><![CDATA[Immucor Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31748</guid>
		<description><![CDATA[Immucor (BLUD) is scheduled to report its third quarter fiscal 2010 results on March 31, 2010. The Zacks Consensus Estimate for the quarter is pegged at a profit of 28 cents. Going by past trends, Immucor has surpassed expectations in the past four quarters. The company had a positive surprise of 20% and 7.69% in the first and second quarters of fiscal 2010, respectively, with a positive four-quarter average of 19.13%. This means that, on an average, the company has topped the Zacks Consensus Estimate by 19.13% over the last four quarters. If third quarter earnings meet our expectation, it will represent a 3.7% year-over-year growth. Immucor’s main products – traditional reagents, capture reagents and instruments have recorded robust growth in the past few quarters, a trend we expect to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/29/blud-immucor-third-quarter-2010-earnings-preview/31748/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BLUD) Immucor Beats Earnings Estimates</title>
		<link>http://www.stockbloghub.com/2010/01/08/blud-immucor-beats-earnings-estimates/24461</link>
		<comments>http://www.stockbloghub.com/2010/01/08/blud-immucor-beats-earnings-estimates/24461#comments</comments>
		<pubDate>Fri, 08 Jan 2010 20:34:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BLUD]]></category>
		<category><![CDATA[Immucor Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24461</guid>
		<description><![CDATA[Immucor (BLUD) announced second quarter 2010 earnings per share of 28 cents, which was better than the Zacks Consensus Estimate of 26 cents and the year-ago quarter’s 24 cents. Net income for the quarter was $19.7 million, compared with $17.3 million for the same quarter last year. The company reported $82.6 million in revenues, an increase of 13% from $73 million in the corresponding period last year. The increase in revenues was based on both price and volume contributions, as well as a positive impact of $1.9 million due to foreign exchange fluctuations. While Immucor recorded robust growth in its top line, its gross margin suffered due to costs related to the company’s Quality Process Improvement Project, targeted at establishing a better quality system. The project, expected to be completed ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/08/blud-immucor-beats-earnings-estimates/24461/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BLUD) Immucor Beats Estimates &#8211; Reaffirmed Fiscal 2010 Revenue and Earnings Guidance</title>
		<link>http://www.stockbloghub.com/2009/10/06/blud-immucor-beats-estimates-reaffirmed-fiscal-2010-revenue-and-earnings-guidance/16646</link>
		<comments>http://www.stockbloghub.com/2009/10/06/blud-immucor-beats-estimates-reaffirmed-fiscal-2010-revenue-and-earnings-guidance/16646#comments</comments>
		<pubDate>Tue, 06 Oct 2009 18:41:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BLUD]]></category>
		<category><![CDATA[Immucor Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=16646</guid>
		<description><![CDATA[Recently, Immucor (BLUD) announced its first quarter (ending August 2009) 2010 earnings of 30 cents, which was better than the Zacks Consensus Estimate of 25 cents and the year ago quarter’s earnings of 28 cents. Net income in the quarter was $21.3 million, compared with $20.0 million for the same quarter last year. The company reported $83.1 million in revenues, an increase of 14% from $73.2 million in the corresponding period last year. The increase in revenues was based on both price and volume contributions, partially offset by foreign exchange fluctuations. While Immucor recorded a robust growth in its top line, its gross margin suffered due to costs related to the company’s Quality Process Improvement Project, targeted at establishing a better quality system. Gross margin during the quarter declined 110 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/06/blud-immucor-beats-estimates-reaffirmed-fiscal-2010-revenue-and-earnings-guidance/16646/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BLUD) Immucor &#8211; third consecutive earnings surprise</title>
		<link>http://www.stockbloghub.com/2008/12/26/blud-immucor-third-consecutive-earnings-surprise/1864</link>
		<comments>http://www.stockbloghub.com/2008/12/26/blud-immucor-third-consecutive-earnings-surprise/1864#comments</comments>
		<pubDate>Fri, 26 Dec 2008 23:53:27 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BLUD]]></category>
		<category><![CDATA[Immucor Inc.]]></category>
		<category><![CDATA[VitalStocks]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=1864</guid>
		<description><![CDATA[Immucor Inc.(BLUD) recently reported a company record for net income in a quarter and completed an acquisition. Earnings are showing solid growth for next year and are traded at a fair value. Company Description Immucor is an international in vitro diagnostic company dedicated to automating manual processes in the hospital/donor laboratory. They develop, manufacture, and sell products used by hospital blood banks, clinical laboratories, and large blood-donor centers to test, detect, and identify certain properties of human blood prior to patient transfusion. Immucor&#8217;s instruments utilize patented solid phase technology reagents to perform ABO grouping tests, RH typing, antibody screening, and platelet cross-matching. Record First Quarter Results On Oct 1 Immucor announced one of the best quarters in company history that included revenues of $73.2 million, a 15% year-over-year increase. About ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/12/26/blud-immucor-third-consecutive-earnings-surprise/1864/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

